We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Will Hear Biogen’s Tofersen Data During March AdComm Meeting
FDA Will Hear Biogen’s Tofersen Data During March AdComm Meeting
At the request of sponsor Biogen, the FDA has extended by three months the new drug application review period for tofersen, an investigational treatment for SOD1 amyotrophic lateral sclerosis — a very rare genetically induced form of the fatal disease.